Islet Cell Tumors (Pancreatic Neuroendocrine Tumors): Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Islet cell tumors — also known as pancreatic neuroendocrine tumors (PNETs) — arise from the endocrine cells of the pancreatic islets of Langerhans and are classified as functioning (hormone-secreting with clinical syndromes) or non-functioning (hormonally silent, detected by mass effect or incidentally). The annual US incidence is approximately 1–1.5 per 100,000, though autopsy series suggest a much higher prevalence of microscopic lesions. Functioning PNETs cause distinct clinical syndromes: insulinoma (hypoglycemia), gastrinoma/Zollinger-Ellison syndrome (peptic ulceration), glucagonoma (necrolytic migratory erythema, diabetes), VIPoma (watery diarrhea), and somatostatinoma (diabetes, cholelithiasis, steatorrhea). Most PNETs are sporadic; 10–20% occur in the context of hereditary syndromes including Multiple Endocrine Neoplasia type 1 (MEN1), VHL disease, NF1, and tuberous sclerosis. WHO 2022 grading (G1–G3, well-differentiated vs. poorly differentiated NEC) integrates Ki-67 proliferation index to stratify prognosis and guide treatment selection.

Sporadic PNETs harbor characteristic somatic mutations involving epigenetic regulation and mTOR pathway signaling. The most frequent somatic alterations in sporadic PNETs are MEN1 gene mutations (approximately 40%), DAXX or ATRX mutations (chromatin remodeling, approximately 25%, associated with alternative lengthening of telomeres), and mTOR pathway mutations involving TSC2, PTEN, and PIK3CA. Hereditary syndromes causing PNETs include Multiple Endocrine Neoplasia type 1 (MEN1, autosomal dominant, germline MEN1 mutations — PNETs in 40–80% of MEN1 patients including gastrinoma and non-functioning PNETs), VHL disease (pancreatic NETs in 10–15% of VHL patients), neurofibromatosis type 1 (NF1, duodenal somatostatinomas), and tuberous sclerosis (TSC1/TSC2 mutations). Sporadic insulinomas are benign in greater than 90% of cases; malignant potential increases proportionally with tumor size greater than 2 cm and with non-functioning tumor type.

Functioning PNETs cause hormone-specific syndromes. Insulinoma: Whipple's triad — hypoglycemic symptoms (diaphoresis, palpitations, tremors, confusion, neuroglycopenia progressing to loss of consciousness) during fasting or exercise, documented blood glucose less than 50 mg/dL, and rapid relief after glucose administration. Gastrinoma (Zollinger-Ellison syndrome): severe refractory peptic ulceration (often multiple, distal duodenal/jejunal), diarrhea, esophageal reflux, and complications including hemorrhage and perforation. Glucagonoma: the characteristic necrolytic migratory erythema (NME) — migratory, blistering, crusting skin rash on the perineum, groin, and extremities — combined with new-onset or worsening diabetes mellitus, deep vein thrombosis, and significant weight loss. VIPoma: profuse watery diarrhea (greater than 3 liters/day), hypokalemia, and achlorhydria (WDHA or Verner-Morrison syndrome). Non-functioning PNETs present late as incidental findings, epigastric discomfort, or with a palpable abdominal mass from large tumor size or liver metastases.

Ga-68 DOTATATE PET-CT (using gallium-labeled somatostatin analogue) is the most sensitive and specific imaging modality for somatostatin receptor-positive PNETs, dramatically superior to conventional OctreoScan scintigraphy and CT alone. Endoscopic ultrasound (EUS) is the most sensitive technique for small pancreatic body and tail PNETs and provides tissue via EUS-guided FNA. Serum chromogranin A is the most useful general neuroendocrine biomarker (elevated in greater than 70% of PNETs); specific hormone assays — fasting insulin/C-peptide, gastrin, glucagon, VIP, somatostatin, PP — confirm functioning tumor type. Supervised 72-hour fast provokes and documents insulin-mediated hypoglycemia in insulinoma (insulin greater than 3 μU/mL with glucose less than 55 mg/dL at nadir). WHO 2022 grading: G1 (Ki-67 less than 3%, low grade), G2 (3–20%, intermediate), G3 (greater than 20%, high grade); well-differentiated G3 PNETs are distinct from poorly differentiated NEC. AJCC TNM staging and ENETS staging systems provide prognostic classification.

Surgical resection is the only curative treatment for localized PNETs. Insulinoma: enucleation (for solitary accessible tumors) or distal pancreatectomy — cure in greater than 95% of benign insulinomas. Gastrinoma: proton pump inhibitor therapy (high-dose omeprazole or lansoprazole) controls acid hypersecretion and peptic complications; resection of the primary for sporadic localized disease; MEN1-associated gastrinomas are rarely surgically curable. Glucagonoma/VIPoma/non-functioning PNET: surgical resection (distal pancreatectomy, Whipple procedure) for resectable disease. Advanced/metastatic G1–G2 PNETs: somatostatin analogues — octreotide LAR 30 mg monthly or lanreotide 120 mg monthly — reduce hormone hypersecretion, control symptoms, and exert antiproliferative effects. Targeted therapy: everolimus 10 mg daily (mTOR inhibitor, RADIANT-3: median PFS 11.0 vs 4.6 months vs placebo) or sunitinib 37.5 mg daily (VEGFR inhibitor) for progressive PNETs. Lu-177 DOTATATE (Lutathera PRRT, 7.4 GBq × 4 doses): NETTER-1 trial demonstrated significantly improved PFS (not reached vs 8.4 months vs high-dose octreotide) for somatostatin receptor-positive progressive midgut NETs; similarly effective in pancreatic NETs. Hepatic-directed therapy (TACE, SIRT/Y-90) for liver-dominant disease.

Prognosis is largely determined by WHO grade, stage, and histological differentiation. Benign insulinoma: cure rate greater than 95% with surgical enucleation. Well-differentiated G1 PNETs with liver metastases: 5-year survival 70–80% due to indolent biology, often compatible with years of surveillance or intermittent therapy. G2 PNETs: approximately 55–60% 5-year survival with metastatic disease. G3 well-differentiated PNETs: approximately 30–40% 5-year survival. Poorly differentiated G3 neuroendocrine carcinoma (NEC): less than 20% 5-year survival with cisplatin-etoposide based chemotherapy. MEN1-associated PNETs are generally more indolent with better prognosis than sporadic PNETs of equivalent size and grade. The prognosis for Islet Cell Tumors (Pancreatic Neuroendocrine Tumors): Causes, Symptoms, Diagnosis and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.

Genetic testing for germline MEN1, VHL, NF1, and TSC1/2 mutations is recommended for patients diagnosed with PNET under age 35, patients with multiple pancreatic neoplasms, those with coexisting endocrine tumors of the pituitary or parathyroid glands, and individuals with a first-degree family history of MEN1 or other hereditary endocrine tumor syndromes. MEN1 mutation carriers require annual biochemical surveillance (fasting calcium, PTH, prolactin, gastrin, insulin/glucose, chromogranin A) and periodic cross-sectional pancreatic imaging (MRI or EUS) beginning at age 20–25 to detect pancreatic NETs while still resectable. VHL mutation carriers need dedicated pancreatic MRI or CT at regular intervals. Alcohol cessation and maintaining healthy body weight may reduce risk of sporadic pancreatic pathology, though specific PNET prevention is unestablished. No general population screening is recommended for PNETs in the absence of hereditary syndrome.

Consult a physician urgently for recurring episodes of sweating, palpitations, confusion, or loss of consciousness — particularly those triggered by fasting, exercise, or delayed meals — which may represent hypoglycemia from an insulinoma. These episodes should be documented with simultaneous blood glucose measurement during symptoms. Seek evaluation for new-onset or worsening peptic ulcer disease that fails standard acid-suppression therapy, particularly if multiple ulcers or ulcers in unusual locations (distal duodenum, jejunum) are found — this pattern suggests Zollinger-Ellison syndrome from gastrinoma. A new skin rash with blistering, crusting, and migratory spread in an area around the groin or perineum combined with new diabetes or weight loss warrants evaluation for glucagonoma. Any unexplained incidentally discovered pancreatic mass should be evaluated by a gastroenterologist or endocrinologist with expertise in neuroendocrine tumors. Patients with MEN1 syndrome or family history of multiple endocrine tumors should be under structured surveillance with an endocrinology team specializing in hereditary endocrine neoplasia.